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Abstract
Cell proliferation is dependent on mitogenic signalling. When absent, normal cells cannot pass the
G1 restriction point, resulting in cell cycle arrest. Passage through the G1 restriction point involves
inactivation of the retinoblastoma protein family. Consequently, loss of the retinoblastoma protein
family leads to loss of the G1 restriction point. Recent work in our lab has revealed that cells
possess yet another mechanism that restricts proliferation in the absence of mitogens: arrest in the
G2 phase of the cell cycle. Here, we discuss the similarities and differences between these
restriction points and the roles of cyclin-dependent kinase inhibitors (CKIs) herein.
Introduction
During each division cycle, cells need to duplicate their
genome and distribute the two copies equally over the
two daughter cells. The processes of DNA-duplication (S-
phase) and cell division (mitosis) are separated by two
gap phases, G1 and G2, respectively. During these phases,
several mechanisms operate to prevent cells from contin-
uing the cell cycle under inappropriate conditions such as
the absence of growth factors or the presence of DNA
damage. The gap phases provide a window of time during
which cells assess whether the environment still favours
proliferation (during G1) or whether S-phase was per-
formed correctly (during G2). If this is not the case, nor-
mal cells can interrupt the cell cycle in the gap phases
through growth inhibitory mechanisms that activate the
retinoblastoma proteins or the p53 transcription factor. In
cancer cells, these growth inhibitory pathways are often
disrupted, leading to unscheduled proliferation[1].
The G1 restriction point
One critical environmental factor for cell proliferation is
the presence of growth factors and normal cells respond
to their absence with cell cycle arrest in G1. However, dur-
ing the G1 phase, growth factors are only required until 2–
3 hours prior to initiation of S-phase[2]. This moment in
G1 was first described in 1974 by Arthur Pardee and
termed the restriction point R. Pardee found that cells that
have passed the G1 restriction point can progress through
S-phase and complete mitosis independently of
mitogens[3]. Since entry into S-phase after growth factor
induction was found to rely on protein synthesis, it was
suggested that cells need to accumulate a protein in order
to pass the restriction point[4]. This hypothetical protein
was referred to as the R-protein, and is apparently induced
by mitogens. Importantly, Pardee found that the restric-
tion point was defective in cancer cell lines, providing
physiological relevance for the restriction point. In addi-
tion, cancer cells were much more resistant to inhibition
of protein synthesis, suggesting that the R-protein was
either stabilized in these cells or not required[5]. The
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simian virus 40 (SV40)[2]. The finding that the oncogenic
products of DNA tumor viruses, such as SV40 large T anti-
gen, adenovirus E1A and HPV E7, disrupt G1/S control
through their inhibitory interaction with the retinoblast-
oma gene product[6,7], provided a crucial link to the
machinery underlying the restriction point.
The retinoblastoma gene encodes a 105 kD nuclear phos-
phoprotein (pRB) that in its unphosphorylated state can
bind to and repress E2F transcription factors whose activ-
ity is essential for G1/S transition [8-12]. Since pRB is
dephosphorylated late in mitosis by PP1 phos-
phatase[13], it needs to be phosphorylated during G1 to
allow entry into S-phase and this requires mitogenic sig-
nalling. Mitogenic signalling results in increased tran-
scription and stabilization of CYCLIN D [14], which
stimulates its catalytic partners CDK4 and CDK6 to phos-
phorylate pRB early in G1, causing partial inactivation of
pRB and release of E2F[15]. E2F transcription factor activ-
ity results in increased transcription of several genes
involved in cell cycle progression among which CYCLIN
E. CYCLIN E/CDK2 activity phosphorylates pRB to a
higher extent, triggering full release of E2F and onset of S-
phase. Conversely, in the absence of mitogens, decreased
transcription of CYCLIN D1 and decreased stability of
CYCLIN D1 protein favor the pRB unphosphorylated
state, which inhibits E2F activity and causes cell cycle
arrest in G1. Additionally, mitogen deprivation causes
accumulation of the cyclin dependent kinase inhibitor
(CKI) p27KIP1 through activation of the FOXO transcrip-
tion factor[16,17]. p27KIP1 is a potent inhibitor of CYCLIN
E/CDK2 kinase activity[18], and will therefore prevent
inactivation of pRB.
Somewhat unexpectedly, Rb-deficient mouse embryonic
fibroblasts (MEFs) still arrested in G1 when mitogen
starved, although a small fraction of the cells could enter
S-phase[19,20]. This has been explained by the activity of
two other retinoblastoma protein family members, p130
and p107, which have redundant functions in regulating
E2F transcription factors[21]. Together, these proteins
make up the so-called family of pocket proteins, which
refers to their highly conserved 'pocket-region' that is
essential for interacting with E2Fs[10,22,23]. Indeed,
MEFs that have lost all three pocket proteins are no longer
capable of arresting in G1 when mitogen starved[24,25].
The retinoblastoma proteins can thus be seen as molecu-
lar switches that operate at the restriction point: when
switched -off- by mitogens, they allow passage through the
restriction point and initiation of S-phase, while the -on-
state results in cell cycle arrest. The downstream target of
the switches are the E2F transcription factors, whose activ-
ity results S-phase entry[12]. The switches are operated by
cyclin-associated kinase activities in G1 that can be modu-
lated by the stability of the cyclin subunit, as is the case for
CYCLIN D, or by inhibition of the kinase activity, as is the
case for CYCLIN E/CDK2. CYCLIN D has been suggested
as an appropriate candidate for the R-protein[26], since it
is dependent on mitogens for its synthesis, is destabilized
in the absence of mitogens and operates the 'molecular
switch'. However, ablation of all three CYCLIN D family
members (Cyclin D1, D2 and D3) did not block re-stimu-
lation of serum-arrested cells (i.e., 60–80% of the cells
were able to re-enter the cell cycle when stimulated with
10% serum)[27]. In contrast, MEFs in which both CYC-
LIN E family members (CYCLIN E1 and E2) were ablated,
failed to re-enter the cell cycle after mitogen deprivation
due to failure in loading MCM proteins to the DNA,
which is essential for S-phase initiation[28,29]. Since
CYCLIN E accumulates during G1 and its ablation results
in failure of cell cycle re-entry, CYCLIN E may be a good
candidate for the R-protein[30].
Mitogen dependence of Rb/p107/p130-deficient 
MEFs
Pardee originally suggested that once cells have passed the
restriction point, the cell cycle can proceed independently
of mitogens until mitosis[2]. Accordingly, ablation of the
retinoblastoma gene family, resulting in complete loss of
the G1 restriction point[24,25], should allow mitogen-
independent proliferation. However, this was shown not
to be the case: pocket-protein deficient cells are prevented
from entering mitosis in the absence of mitogens by two
mechanisms: (1) the majority of cells undergoes apopto-
sis[24,25,31]; (2) surviving cells arrest in the G2 phase of
the cell cycle within 3–5 days[31]. Apparently, mitogenic
signaling is not only required for passing the G1 restriction
point, but also for passage through G2. While activation of
the G1 restriction point in normal cells involves inhibition
of D- and E-type cyclins, mitogen-starvation-induced G2
arrest is effected by accumulation of p27KIP1 and p21CIP1
that act as inhibitors of CYCLIN B1- and CYCLIN A-asso-
ciated kinase activities[31].
CKI mediated inhibition of CDK1, the catalytic partner of
CYCLIN B1, has been described in other systems as well.
In addition to its CDK2-inhibiting activity[32], p21CIP1
was shown to induce a G2 arrest upon DNA damage[33]
or upon over-expression[34] by inhibiting CDK1 kinase
activity through direct interaction. In contrast to an earlier
report[18], recent work from several laboratories has
revealed that also p27KIP1 can inhibit CDK1 kinase activity
through direct interaction. E.g., p27KIP1 is highly expressed
in thymocytes and splenocytes and binds to and inhibits
CYCLIN B1-CDK1 kinase activity in these cells[35]. In
mice, ablation of SKP2, an F-Box protein that targets
p27KIP1 to an SCF ubiquitin-ligase complex, resulted in
elevated p27KIP1 levels associated to CDK1. Most defectsPage 2 of 5
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CDK2 kinase activities and can be rescued by concomitant
ablation of p27KIP1, which restores physiological cyclin-
dependent kinase activities[36].
G2 arrest: a second restriction point?
The mitogen-starvation-induced G2 arrest shows several
similarities to the G1 restriction point. E.g., both depend
on inhibition of cyclin-associated kinase activities and in
both, accumulation of p27KIP1 plays an important
(although not exclusive) role[31]. Importantly, both are
reversible: mitogen stimulation of G2-arrested pocket-pro-
tein-deficient cells results in reactivation of the cell cycle
and synchronous entry into mitosis after approximately
15 hours. Is there also a true restriction point in G2 in the
sense that a time point can be identified after which cells
do no longer require serum to enter mitosis? To address
this issue, we serum-starved pocket-protein deficient
MEFs for 7 days, and then re-fed the cells with serum-con-
taining medium at time point 0. At several time points
hereafter, we replaced the serum-containing medium for
serum-free medium. To quantify G2 exit, we trapped the
cells in mitosis using the microtubule-stabilizing drug
Taxol. 21 hours after serum-stimulation, we harvested the
cells and determined the mitotic fraction by FACS-stain-
ing for the mitotic marker MPM2 as described previ-
ously[31]. Figure 1A shows that the fraction of cells
entering mitosis gradually increased upon longer dura-
tion of serum exposure. However, at 6 hours of serum
exposure, the maximum amount of mitotic cells was
reached. This indicates that mitogen-starved G2 arrested
cells only required a window of 3–6 hours of serum in
order to re-enter the cell cycle, identifying a G2 restriction
point at approximately 10 hours before mitotic entry.
Next, we wondered whether cell cycle re-entry of serum-
starved G2-arrested cells relies on protein translation, as
was previously shown for recovery from G1 arrest. We
therefore compared serum stimulation of G2-arrested cells
in the presence and absence of the translation inhibitor
cycloheximide. Figure 1B shows that inhibition of protein
synthesis precluded cell cycle re-entry of serum-stimulated
cells. This suggests that passage through the G2 restriction,
like passage through the G1 restriction point, depends on
synthesis of one or multiple proteins.
An important question now is: why was the G2 restriction
point not identified in the original experiments of Pardee?
A first explanation is that activation of pocket proteins in
serum-starved normal cells (i.e., wild type MEFs) imposes
an arrest in G1 that largely prevents subsequent cell cycle
events. However, if cells possess two restriction points,
and mitogen deprivation results in inhibition of all cyclin-
associated kinase activities, why then do normal cells
mainly arrest in G1 and is G2 arrest only seen in pocket-
protein compromised MEFs? One reason could be that the
levels of suppression of CYCLIN/CDK activity required for
G1 or G2 arrest are different. In wild type cells, minor inhi-
bition of D- and E-type cyclins may already impose a G1
arrest through accumulation of hypophosphorylated
pocket proteins. In contrast, G2 arrest imposed by inhibi-
tion of CYCLIN A- and B kinase activities requires high
levels of p21CIP1 and p27KIP1, which need several days to
accumulate. Apparently, when these levels are reached in
pocket-protein-deficient cells, the remaining CDK2 kinase
activity is still sufficient to drive cells through S-phase,
while the remaining CDK1 activity is too low to allow
entry into mitosis, resulting in G2 arrest.
Secondly, G2 arrest in serum-starved, pocket-protein
defective cells relies on functional p53[31]. The cancer cell
Evidence for a G2 restriction pointFigure 1
Evidence for a G2 restriction point. A. Cell cycle re-
entry from G2 requires 6 hours of mitogen-stimulation. 
Serum-starved cells were stimulated by the addition of 
serum-containing medium. Subsequently, at the indicated 
times medium was replaced with serum-free medium con-
taining Taxol for the last 9 hours. At 21 hours cells were har-
vested and fixed in 70% ethanol and mitotic entry was 
determined by MPM2 FACS staining. Error bars indicate the 
standard deviation for two experiments. B. Cell cycle re-
entry from G2 requires protein synthesis. Serum-starved cells 
were serum-stimulated in the absence or presence of 50 µg/
ml cycloheximide (CHX). Cells were fixed at 21 hours and 
mitotic entry was determined by MPM2 FACS staining. The 
level of MPM2 positivity in serum-stimulated cells at 21 hours 
is set at 100%.Page 3 of 5
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SV40 Large T antigen, which inactivates the pocket pro-
teins, but also p53[37]. Therefore, both the G1 and the G2
restriction points were inactivated in these cells.
Conclusion
The G1 restriction point defines a window of mitogen
requirement in G1. However, in the absence of pocket pro-
tein activity, another growth-restricting mechanism in G2
becomes manifest that prevents unconstrained prolifera-
tion under mitogen-starved conditions. This G2 arrest has
the following features:
1. It allows cell cycle progression only in the presence of
mitogens.
2. It is reversible: mitogen-starved, G2-arrested cells re-
enter the cell cycle synchronously upon mitogen stimula-
tion.
3. A specific moment in G2 exists, approximately 10 hours
before mitotic entry, after which cells can progress into
mitosis independently of mitogens.
4. Recovery from G2 arrest relies on accumulation of one
or multiple proteins.
5. The G2 arrest is effectuated by inhibition of CYCLIN-
CDK activity through association with CKIs.
These properties of serum-starvation induced G2 arrest
identify a true restriction point in G2. However, the G1 and
G2 restriction points are not completely identical at the
molecular level. For one: whereas the G1 restriction point
critically depends on the activity of the pocket proteins,
the G2 restriction point only becomes manifest when
pocket protein activity is diminished or absent. Further-
more, the G1 restriction point involves degradation of
CYCLIN D in addition to CKI-mediated inhibition of
CYCLIN E, whereas the G2 restriction point appears to rely
solely on CKI-mediated inhibition of CYCLIN A- and
CYCLIN B- associated kinase activities.
Taken together, we postulate that cells possess two restric-
tion points defining the requirement for mitogenic signal-
ing in G1 and in G2 to stimulate CYCLIN D/E and CYCLIN
A/B kinase activities, respectively (Fig. 2A). In both, accu-
mulation of p27KIP1 plays an important role. When
growth factors are removed from normal cells, rapid dis-
appearance of CYCLIN D1 and inhibition of CYCLIN E by
accumulation of p27KIP1 results in hypophosphorylated
pRB, low E2F activity and G1 arrest (Fig. 2B). In cells that
have lost the pocket proteins and hence the G1 restriction
point, the G2 restriction point comes into play. Accumula-
tion of p21CIP1 and p27KIP1 apparently leaves sufficient
CDK2 activity to allow cells to cross the G1/S border and
complete S phase (likely because of elevated E2F activity
in the absence of pocket proteins). However, inhibition of
CYCLIN A- and B kinase activity now arrests cells in G2
(Fig. 2C).
We envisage that the G2 restriction point serves as a
backup mechanism to prevent unconstrained prolifera-
tion of cells that have lost proper G1/S control. Indeed, a
substantial amount of circumstantial evidence suggests a
role for the G2 restriction point in the suppression of can-
cer[38]. E.g., it is possible that tumor cells in a primary
tumor retain a normal G2 arrest that does not perturb pro-
liferation at the site of origin but only becomes activated
under special conditions such as dissemination to distant
sites. Indeed, occult, non-proliferating tumor cells that
were found in the bone marrow and bloodstream of can-
cer patients without overt metastases, may present an
example of this scenario[39]. Elucidation of the mecha-
nism of cell cycle arrest is of paramount importance to
control the behavior of such cells.
Abbreviations
MEFs: mouse embryonic fibroblasts
Extending the restriction pointFigure 2
Extending the restriction point. A. Cell cycle progres-
sion is dependent on CYCLIN-CDK kinase activity. B. 
Mitogen starvation results in cell cycle arrest in G1 through 
degradation or suppression of CYCLIN D and CKI-mediated 
inhibition of CYCLIN E-CDK2. C. Unscheduled passage 
through the G1 restriction point in the absence of mitogens 
(e.g., through RB loss) results in cell cycle arrest in G2.Page 4 of 5
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